文章：

修订后的国际分期系统在新诊断及复发多发性骨髓瘤患者中的临床价值

Clinical utility of the Revised International Staging System in unselected patients with newly diagnosed and relapsed multiple myeloma

原文发布日期：2017-02-17

DOI: 10.1038/bcj.2017.13

类型: Original Article

开放获取: 是

英文摘要：

We analyzed the utility of Revised International staging system (RISS) in an unselected cohort of newly diagnosed multiple myeloma (NDMM; cohort 1), and relapsed/refractory multiple myeloma (RRMM; cohort 2) patients. Cohort 1 included 1900 patients seen within 90 days of diagnosis, from 2005 to 2015, while cohort 2 had 887 patients enrolled in 23 clinical trials at Mayo Clinic. The overall survival (OS) and progression-free survival (PFS) was calculated from the time since diagnosis or trial registration. The median estimated follow up was 5 and 2.3 years for Cohorts 1 and 2, respectively. Among 1067 patients evaluable in Cohort 1, the median OS and PFS was 10 and 2.8 years for RISS stage I, 6 and 2.7 years for RISS stage II and 2.6 and 1.3 years for RISS stage III (P<0.0001). Among 456 patients evaluable in Cohort 2, the median OS and PFS was 4.3 and 1.1 years for RISS stage I, 2 and 0.5 years for RISS stage II and 0.8 and 0.2 years for RISS stage III (P<0.0001). In conclusions, RISS gives a better differentiation of NDMM as well as RRMM patients into three survival subgroups and should be used to stratify patients in future clinical trials.

摘要翻译： 

我们在一组未经选择的新诊断多发性骨髓瘤患者（队列1）和复发/难治性多发性骨髓瘤患者（队列2）中分析了修订版国际分期系统的实用性。队列1包括2005年至2015年间确诊90天内就诊的1900例患者，而队列2包含887例参与梅奥诊所23项临床试验的患者。总生存期和无进展生存期自确诊或试验注册之日起计算。队列1和队列2的中位估计随访时间分别为5年和2.3年。在队列1中可评估的1067例患者中，RISS分期I、II、III期的中位总生存期和无进展生存期分别为10年与2.8年、6年与2.7年、2.6年与1.3年。在队列2中可评估的456例患者中，RISS分期I、II、III期的中位总生存期和无进展生存期分别为4.3年与1.1年、2年与0.5年、0.8年与0.2年。综上所述，RISS能更好地区分新诊断及复发/难治性多发性骨髓瘤患者的三个生存亚组，应在未来临床试验中用于患者分层。

原文链接：

Clinical utility of the Revised International Staging System in unselected patients with newly diagnosed and relapsed multiple myeloma